Dual-time point scanning of integrated FDG PET/CT for the evaluation of mediastinal and hilar lymph nodes in non-small cell lung cancer diagnosed as operable by contrast-enhanced CT

McLoud, 1992, Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling, Radiology, 182, 319, 10.1148/radiology.182.2.1732943 Webb, 1991, CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group, Radiology, 178, 705, 10.1148/radiology.178.3.1847239 Tahara, 2000, Is there a role for routine mediastinoscopy in patients with peripheral T1 lung cancers?, Am J Surg, 180, 488, 10.1016/S0002-9610(00)00509-2 Yasufuku, 2006, Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer, Chest, 130, 710, 10.1378/chest.130.3.710 Duhaylongsod, 1995, Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET), J Thorac Cardiovasc Surg, 110, 130, 10.1016/S0022-5223(05)80018-2 Lardinois, 2003, Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography, N Eng J Med, 348, 2500, 10.1056/NEJMoa022136 Kang, 2004, Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours, Eur J Nucl Med Mol Imaging, 31, 202, 10.1007/s00259-003-1368-x Vansteenkiste, 1998, Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients, J Clin Oncol, 16, 2142, 10.1200/JCO.1998.16.6.2142 Matthies, 2002, Dual time point 18F-FDG PET for the evaluation of pulmonary nodules, J Nucl Med, 43, 871 Demura, 2003, 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax, J Nucl Med, 44, 540 Mountain, 1997, Regional lymph node classification for lung cancer staging, Chest, 111, 1718, 10.1378/chest.111.6.1718 Xiu, 2007, Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity, Clin Nucl Med, 32, 101, 10.1097/01.rlu.0000252457.54929.b7 Gallagher, 1978, Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-d-glucose, J Nucl Med, 19, 1154 Kubota, 2001, Advantage of delayed whole-body FDG-PET imaging for tumour detection, Eur J Nucl Med, 28, 696, 10.1007/s002590100537 Dobert, 2004, Limitations of dual time point FDG-PET imaging in the evaluation of focal abdominal lesions, Nuklearmedizin, 43, 143, 10.1055/s-0038-1625195 Yen, 2005, Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes?, Eur J Nucl Med Mol Imaging, 32, 541, 10.1007/s00259-004-1719-2 Hustinx, 1999, Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck, Eur J Nucl Med, 26, 1345, 10.1007/s002590050593 Nakamoto, 2000, Delayed 18F-fluoro-2-deoxy-d-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas, Cancer, 89, 2547, 10.1002/1097-0142(20001215)89:12<2547::AID-CNCR5>3.0.CO;2-V